L'Air Liquide S.A. AI.PA
Composite 53/100; the shares have moved about 18% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 24/100 — a strong mark against it.
Quality ranks 67/100 — a moderate point in its favour. Momentum ranks 64/100 — a moderate point in its favour. Balance-sheet strength ranks 60/100 — a slight point in its favour.
Valuation ranks 24/100 — a strong mark against it. Growth ranks 43/100 — a slight mark against it.
What the company does L'Air Liquide S.A. supplies industrial and medical gases, technologies, and services to sectors including chemicals, refining, healthcare, and electronics across Europe, the Americas, and Asia Pacific. Its Gas & Services segment serves large industries, healthcare, and electronics, while Engineering & Construction delivers tailored solutions.
Key financials Revenue declined 3.4% year-over-year, but net income rose 5.3%. Margins remain robust: gross 64.2%, operating 19.5%, and net 13.1%. ROE stands at 13.4%, with debt/equity at 0.63 and net debt/EBITDA at 1.98. Dividend yield is 1.9% with a payout ratio of 60.5%.
Stock health Momentum is mixed: 12-month return 13.19%, but down 5.91% from its 52-week high. RSI(14) is 44.20, indicating neutral momentum. Sideravia scores it average quality (50.1) but richly valued (26.0), with strong income (69.9) and momentum (64.4).
Price vs fair value The stock trades at a PREMIUM of 71.70% to our fair-value estimate and a discount of 13.43% to the analyst 12-month target. - Q2 2026 earnings call highlights strong growth despite currency headwinds (GuruFocus.com) - WSJ notes management reaffirmed guidance after revenue and margin improvements (The Wall Street Journal) - Valuation percentile of 26.0/100 signals rich pricing relative to peers (Sideravia)
Looking forward Forward P/E of 26.18 and PEG of 1.17 suggest moderate growth expectations. Analysts see potential upside to 194.52, implying ~13% upside from the current price. Focus remains on margin stability and execution in core industrial and healthcare markets.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.